Truist Financial Corp Sells 18,116 Shares of Boston Scientific Corporation $BSX

Key Points

• Truist Financial Corp reduced its stake in Boston Scientific Corporation by 7.3%, selling 18,116 shares, leaving it with 229,563 shares valued at approximately $24.66 million.
• Boston Scientific reported a 22.8% year-over-year revenue growth for the quarter, with earnings of $0.75 per share exceeding analysts' expectations.
• Institutional investors hold a significant majority, with 89.07% of Boston Scientific's shares owned by larger investment firms.

Truist Financial Corp trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 7.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 229,563 shares of the medical equipment provider's stock after selling 18,116 shares during the period. Truist Financial Corp's holdings in Boston Scientific were worth $24,657,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Invesco Ltd. increased its position in shares of Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after purchasing an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the last quarter. Amundi grew its position in Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after buying an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Boston Scientific by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider's stock valued at $1,139,938,000 after buying an additional 460,580 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Up 1.1%

BSX opened at $97.30 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The firm has a 50-day simple moving average of $102.93 and a two-hundred day simple moving average of $102.05.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $0.62 earnings per share. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on BSX shares. Needham & Company LLC restated a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Wednesday. Truist Financial boosted their price objective on Boston Scientific from $125.00 to $129.00 and gave the company a "buy" rating in a research note on Wednesday. Royal Bank Of Canada reiterated an "outperform" rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of Boston Scientific in a research report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $120.79.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.